Mark Your Calendars: BriaCell’s Annual Shareholder Meeting Rescheduled to February 5, 2025!
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company’s Annual General Meeting of Shareholders (the “Meeting”), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled.
The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed Meeting. The Meeting has been postponed due to delays stemming from the disruption in postal service in Canada, and to provide further time to solicit proxies from the Company’s shareholders.
BriaCell Therapeutics Corp. is a company dedicated to developing innovative immunotherapies for cancer treatment. The rescheduling of their Annual Shareholder Meeting is a significant event that allows shareholders to participate in important decisions regarding company operations and future directions.
The disruption in the postal service in Canada has caused delays in communication, leading to the decision to reschedule the meeting. This change provides shareholders with additional time to prepare for the meeting and ensures that all stakeholders have the opportunity to participate effectively.
By rescheduling the Annual General Meeting to February 5, 2025, BriaCell is prioritizing transparency and accountability to its shareholders. This decision reflects the company’s commitment to open communication and active shareholder engagement.
How will this affect me?
As a shareholder of BriaCell Therapeutics Corp., the rescheduling of the Annual Shareholder Meeting to February 5, 2025, gives you more time to plan and participate in the decision-making process of the company. It ensures that you have the opportunity to voice your opinions and concerns regarding the company’s operations and future developments.
How will this affect the world?
The rescheduling of BriaCell’s Annual Shareholder Meeting reflects the company’s dedication to transparency and effective communication with its stakeholders. By prioritizing shareholder engagement and ensuring all parties have a voice in company decisions, BriaCell sets a positive example for other biotechnology companies. This commitment to accountability and openness can contribute to building trust with investors and fostering innovation in cancer treatment worldwide.
Conclusion:
In conclusion, the rescheduling of BriaCell’s Annual Shareholder Meeting to February 5, 2025, demonstrates the company’s commitment to shareholder engagement and transparent communication. This event emphasizes the importance of active participation in company decisions and highlights BriaCell’s dedication to transforming cancer care through innovative immunotherapies.
